Subcutaneous semaglutide, a long-acting GLP-1 RA, is one of the most potent molecules of the class approved for T2D, and recently, its potential therapeutic effect on hepatic steatosis has been reported, also because the expression of the GLP-1 receptor in liver parenchyma is still a debated issue [12]. This evidence concerns the gene GLP1R and Hepatic steatosis.